Biotech Private Placements...at Premiums
This article was originally published in Start Up
Executive Summary
Contrary to assumptions, public biotech companies can actually sell their equity privately at premiums to their 3-month average trading price. As for illiquidity, the bane of the biotech investor: it may actually help some companies increase their offering prices.